RxDoctor Payments Data

Rebekah White, MD

Surgical Oncology · San Diego, CANPI 1750400784

Payments from drug & device makers

What this record shows

7 manufacturers reported payments, led by Angiodynamics, Inc. at 39.0% of the total. Reporting peaked in 2022 at $884 and has fallen 80.4% since, to $173 in 2024.

$2,573in general payments, 2019–2025

Across 11 payments — averaging $233.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$1K
  • Medtronic$750
  • Trisalus Life Sciences, Inc.$332
  • Serpex Medical Inc$173
  • Intuitive Surgical$166
  • AbbVie$134
  • plus $13 from 1 others
$91,500in research payments, 2019–2025

Across 5 payments — averaging $18,300 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Angiodynamics, Inc.$92K

What the payments were for

  • Consulting fees$1,10043%
  • Food & beverage$1,47357%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Angiodynamics, Inc.3$1,004
Medtronic1$750
Trisalus Life Sciences, Inc.2$332
Serpex Medical Inc1$173
Intuitive Surgical1$166
AbbVie2$134
Baxter Healthcare1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,573 in reported general payments places this provider in the 55th percentile of 209 surgical oncology providers in California.

See all surgical oncology providers in California

Medicare billing

Part B allowed, 2024
$75,088
Medicare patients
133
Services billed
284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other surgical oncology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →